KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Current Liabilities (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Total Current Liabilities for 7 consecutive years, with $636.2 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 49.25% to $636.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $636.2 million through Dec 2025, down 49.25% year-over-year, with the annual reading at $636.2 million for FY2025, 49.25% down from the prior year.
  • Total Current Liabilities hit $636.2 million in Q4 2025 for Royalty Pharma, up from $530.8 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $1.3 billion in Q4 2024 to a low of $124.6 million in Q1 2024.
  • Historically, Total Current Liabilities has averaged $627.0 million across 5 years, with a median of $407.4 million in 2021.
  • Biggest five-year swings in Total Current Liabilities: tumbled 88.85% in 2024 and later surged 849.52% in 2025.
  • Year by year, Total Current Liabilities stood at $171.2 million in 2021, then soared by 581.33% to $1.2 billion in 2022, then plummeted by 86.17% to $161.4 million in 2023, then surged by 676.82% to $1.3 billion in 2024, then crashed by 49.25% to $636.2 million in 2025.
  • Business Quant data shows Total Current Liabilities for RPRX at $636.2 million in Q4 2025, $530.8 million in Q3 2025, and $1.2 billion in Q2 2025.